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Drug development is a slow and cumbersome process that includes assessment of new 
pharmaceutical compounds in countless pre-clinical studies and several phases of clinical trials. A 
critical stage is the transition from laboratory experiments to patient studies, whereupon the results 
all too often are disappointing in terms of therapeutic effect. The reason is as simple as it is 
challenging: cell-based experimental models are not always proper representations of human 
disease. Consequently, very few of the numerous tested anticancer drugs perform well enough to 
warrant regulatory approval, despite promising preclinical results. Huge efforts made at research 
centers and pharmaceutical companies are thus not only excruciatingly time consuming and 
expensive, but also - in most cases - futile. Meanwhile, patients in need are waiting for improved 
treatments. 
To address this fundamental problem, Dr. Jim Olson and colleagues in Fred Hutch's Clinical 
Research Division developed a device that enables more accurate and efficient testing of new 
pharmaceutical compounds, together with automated, image-based analysis. The technology 
platform, called CIVO, allows simultaneous testing of multiple drugs and drug combinations directly 
in human tumors, thereby bypassing issues with in vivo distribution, metabolism, excretion etc., 
allowing full focus on the interaction between drugs and cancer cells in an authentic biological 
microenvironment. The CIVO platform is licensed to Presage Biosciences, a Seattle-based company 
that sprung from Dr. Olson's laboratory in 2008. 
The technology and its benefits were demonstrated in the April 2015 issue of Science Translational 
Medicine. In the article, Dr. Olson and associates describe the principle of the handheld device, 
which enables localized administration of microliter volumes of up to eight different drugs per tumor, 
using an array of needles connected to drug reservoirs. The investigators showed results from 
several tumor models, including xenografted mice and canine patients, as well as four human 
lymphoma patients. 
A key factor for allowing simultaneous analysis of multiple compounds is separation between the 
infused agents, also over time. It was demonstrated that more than 96 % of the various injectates 
remained within 2 mm of their respective injection sites, at least up to 24 hours, without crossover 
between the different regions. Besides comparing various drugs and drug combinations, CIVO 
explores yet another dimension: tumor depth. During injection, the needles are pushed into the in-
June 15, 2015 SCIENCE SPOTLIGHT 
 
2 Volume 5, Issue 6 | Fred Hutchinson Cancer Research Center 
 
patient tumor and then slowly pulled out as the drug solution is being infused at a constant flow rate. 
The result is uniform tracks of drugs through the z-axis of the tumor, in a column-like fashion. After 
tumor resection, samples from different depths into the tissue can be used to evaluate both the 
uniformity of response and the effect of different microenvironments on drug efficacy. For instance, 
deeper-lying tumor regions may not be sufficiently vascularized and thereby contain less oxygen. 
Will these hypoxic regions respond differently to treatments? This is one of many questions that may 
be answered using the CIVO platform. 
The investigators found that the system offered safe and efficient drug administration, with very mild 
adverse effects in human patients. To assess clinical predictive ability, comparisons were made in 
mice between microinjection-induced local tumor responses and responses after systemic drug 
delivery. CIVO-injection resulted in tumor growth inhibition that was comparable to that of systemic 
drug delivery, and the investigators successfully predicted both resistance and increased sensitivity 
in tumors of different contexts using the new platform. In addition, an unexpected sensitivity to the 
drug mafosfamide was discovered in otherwise chemotherapy-resistant lymphoma xenografts in 
mice. Importantly, this effect was not revealed using standard in vitrocell assays, underlining their 
relative inadequacy compared with in vivo screening methods. 
According to Dr. Olson, CIVO represents a major step forward towards improved cancer treatments 
by enabling evaluation of resistance or sensitivity to drugs in the context of a patient's own immune 
system. "In some cases, we can identify the specific mechanism of resistance to therapeutic agents," 
he added. 
The long term goal is clear: "To avoid treating patients with chemotherapy that will cause harm but 
provide no benefit - and to find the most effective and least toxic combinations of drugs," Dr. Olson 
said. The immediate plan is to advance the platform and broaden its range of clinical applications. 
Dr. Olson's enthusiasm is contagious: "Wouldn't it be interesting if we could accurately predict which 
patients will fail standard of care agents so that novel therapeutics could be evaluated in first or 
second line regimens instead of third or fourth?" he asked. It sure would! 
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Images provided by Presage Biosciences 
Presage Biosciences' CIVO patented 
arrayed microinjection drug delivery 
device (top) enables simultaneous 
assessment of multiple drugs or drug 
combinations directly in a single solid 
tumor while still in a patient's body. 
Presage analysis shows local response to 
microinjections of eight different cancer 
drugs within a canine patient's sarcoma 
tumor, as visualized by cleaved caspase 
staining in red for regions of apoptotic 
cell death due to drug response 
(bottom). Live tumor cells are shown in 
blue, the green is the injection site dye, 
and the red dots are dead tumor cells 
responding to the injected drugs. 
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